cagrilintide clinical trial New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Trial Scorecard: REDEFINE 1 and

However, we believe obesity and lack of physical activity are the largest contributory factors resulting in a decline in Testosterone levels, discussed in depth in Me & My Fat The Role of Fat on Your Hormonal Health

The research community consensus, articulated in recent systematic reviews, states that BPC-157 should be considered investigational and approached with appropriate caution, but this recommendation stems from limited human clinical data rather than evidence of harm

At meetings scheduled for July 23 and 24 at the FDA's White Oak Campus in Silver Spring, Maryland, the FDA's Pharmacy Compounding Advisory Committee will consider whether to recommend adding seven peptide substances to the agency's 503A Bulks List, which would allow them to be used in certain compounded prescription drugs

Sci STKE